BioCardia unveils interim data that led it to stop PhIII enrollment of heart failure stem cell therapy
BioCardia disclosed that its heart failure stem cell therapy failed to hit on all three measures that comprised the primary endpoint …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
